ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
Dow Jones
38.686,32
1,51%
Euro vs US Dollar
1,08565
-0,01%
Bitcoin
67.641,93
0,24%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Sage Therapeutics Inc (SAGE)

  7. Sage Therapeutics Inc (SAGE) News

SAGE

Sage Therapeutics (SAGE)

Sage Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:SAGE
DatumZeitQuelleÜberschriftSymbolFirma
07/05/202412h30Business WireSage Therapeutics to Participate in Upcoming May Investor ConferencesNASDAQ:SAGESage Therapeutics Inc
25/04/202412h30Business WireSage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business ProgressNASDAQ:SAGESage Therapeutics Inc
17/04/202412h30Business WireSage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s DiseaseNASDAQ:SAGESage Therapeutics Inc
11/04/202412h30Business WireSage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024NASDAQ:SAGESage Therapeutics Inc
28/02/202412h30Business WireSage Therapeutics to Present at Upcoming March Investor ConferencesNASDAQ:SAGESage Therapeutics Inc
21/02/202422h35Edgar (US Regulatory)Form SC TO-I/A - Tender offer statement by Issuer: [Amend]NASDAQ:SAGESage Therapeutics Inc
15/02/202423h02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SAGESage Therapeutics Inc
15/02/202423h02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SAGESage Therapeutics Inc
14/02/202422h09Edgar (US Regulatory)Form SC TO-I/A - Tender offer statement by Issuer: [Amend]NASDAQ:SAGESage Therapeutics Inc
14/02/202413h49Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SAGESage Therapeutics Inc
14/02/202413h20Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:SAGESage Therapeutics Inc
14/02/202412h45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SAGESage Therapeutics Inc
14/02/202412h30Business WireSage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business ProgressNASDAQ:SAGESage Therapeutics Inc
31/01/202423h25Edgar (US Regulatory)Form SC TO-I/A - Tender offer statement by Issuer: [Amend]NASDAQ:SAGESage Therapeutics Inc
31/01/202422h50Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SAGESage Therapeutics Inc
31/01/202412h30Business WireSage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024NASDAQ:SAGESage Therapeutics Inc
24/01/202422h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SAGESage Therapeutics Inc
23/01/202414h13Edgar (US Regulatory)Form SC TO-I - Tender offer statement by IssuerNASDAQ:SAGESage Therapeutics Inc
08/01/202412h45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SAGESage Therapeutics Inc
08/01/202412h32Business WireSage Therapeutics to Provide Business Updates at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:SAGESage Therapeutics Inc
08/01/202412h30Business WireSage Therapeutics Announces Changes to Board of DirectorsNASDAQ:SAGESage Therapeutics Inc
04/01/202422h07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SAGESage Therapeutics Inc
02/01/202412h30Business WireSage Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024NASDAQ:SAGESage Therapeutics Inc
19/12/202314h32Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:SAGESage Therapeutics Inc
19/12/202314h30Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:SAGESage Therapeutics Inc
14/12/202312h30GlobeNewswire Inc.ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.NASDAQ:SAGESage Therapeutics Inc
14/12/202312h30Business WireZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.NASDAQ:SAGESage Therapeutics Inc
08/12/202315h00Edgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNASDAQ:SAGESage Therapeutics Inc
08/12/202314h30Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:SAGESage Therapeutics Inc
08/11/202312h30Business WireSage Therapeutics to Present at Upcoming November Investor ConferencesNASDAQ:SAGESage Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SAGE

Kürzlich von Ihnen besucht

COIN
FLANDERSEUR
ASX
HSOKOQ
LATK
CELRETH
CelerToken
BMF
DDIF28
DDIF28 - Janeiro 2028
USOTC
LIVC
Live Current Media (CE)
BOV
H1FC34
HF Sinclair
LSE
TEX
TEP Exchange
LSE
54YQ
Int.fin. 46
XE
0GZG
BNP Paribas Arbitrage Is...
USOTC
CHBBY
China Bohai Bank (PK)
LSE
0QVR
Scandi Standard Ab (publ)
EU
LOIZF
Region Pays de la Loire ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten